Fermenta Biotech inks exclusive Vitamin B12 tech deal with VIT Vellore
Fermenta Biotech has signed an exclusive license agreement with VIT Vellore for Vitamin B12 Fortification Technology. This technology enables natural in-situ enrichment of Vitamin B12 in fermented foods. The collaboration aims to develop scalable solutions for improved nutritional outcomes. The announcement was made on September 8, 2026.
While a strategic partnership, the immediate financial impact is not quantified and the full commercial potential will be realized in subsequent phases of development and market penetration.
The agreement represents a strategic partnership that is expected to enhance the company's product portfolio and market reach in the growing fortified food sector.
Fermenta Biotech Limited has entered into an exclusive Licence Agreement with Vellore Institute of Technology (VIT) for Vitamin B12 Fortification Technology. This agreement covers VIT's technology for natural in-situ Vitamin B12 fortification in fermented foods, enabling enrichment during the fermentation process itself.
The technology, developed by Dr. Krishnan Venkataraman and his team at VIT Vellore, aims to enhance Vitamin B12 directly within fermented food matrices like curd, idli/dosa batters, and breads, rather than through conventional addition to the final product. Laboratory studies indicated approximately 80% retention of enhanced Vitamin B12 levels after cooking.
Mr. Prashant Nagre, Managing Director of Fermenta Biotech Limited, stated that this collaboration will extend the company's food fortification capabilities and translate emerging nutrition research into scalable solutions. G. Viswanathan, Chancellor of VIT, expressed confidence that the MoU will contribute to India's nutritional science capabilities and the fight against micronutrient deficiency.
The next phase of the collaboration will involve application development, nutritional validation, regulatory evaluation, and the creation of commercially viable solutions. The commercial potential spans FMCG, food and nutrition, nutraceutical, and health-related applications. The announcement was made on September 8, 2026.
What to do with a filing like this
Fermenta Biotech Limited filed this with the NSE as a statutory disclosure, categorised under strategic partnerships. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fermenta Biotech Limited. Read the original for the full detail.